The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Hit Generation
ChemMedChem · 2023
DOI: 10.1002/cmdc.202300002 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ChemMedChem, 2023. Verfasst von Jean Quancard und 10 weiteren Autor:innen. Beteiligte Einrichtung: Global Discovery Chemistry, Novartis Institute for Biomedical Research, Novartis Pharma AG, Novartis Campus, 4056, Basel, Switzerland. Hauptthemen laut MEDLINE: Chemistry, Pharmaceutical, Drug Discovery. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Abstract (Originalsprache)
Hit generation is a crucial step in drug discovery that will determine the speed and chance of success of identifying drug candidates. Many strategies are now available to identify chemical starting points, or hits, and each biological target warrants a tailored approach. In this set of best practices, we detail the essential approaches for target centric hit generation and the opportunities and challenges they come with. We then provide guidance on how to validate hits to ensure medicinal chemistry is only performed on compounds and scaffolds that engage the target of interest and have the desired mode of action. Finally, we discuss the design of integrated hit generation strategies that combine several approaches to maximize the chance of identifying high quality starting points to ensure a successful drug discovery campaign.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Global Discovery Chemistry, Novartis Institute for Biomedical Research, Novartis Pharma AG, Novartis Campus, 4056, Basel, Switzerland.
- Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100, Copenhagen, Denmark.
- School of Life Sciences, University of Sussex, Brighton, BN1 9RH, UK.
- Medicinal Chemistry, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, 43183, Gothenburg, Sweden.
- Medicinal Chemistry, Global R&D, Merck Healthcare KGaA, Frankfurter Straße 250, 64293, Darmstadt, Germany.
- Medicinal Chemistry, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Straße 65, 88397, Biberach an der Riss, Germany.
ORCID-Profile: Jean Quancard, Anna Vulpetti, Anders Bach, Brian Cox, Ingo V Hartung, Stefan Laufer, Josef Messinger, Gianluca Sbardella, Russell Craft
Zitieren
APA
Quancard, J., Vulpetti, A., Bach, A., Cox, B., Guéret, S. M., Hartung, I. V., Koolman, H. F., Laufer, S., Messinger, J., Sbardella, G., & Craft, R. (2023). The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Hit Generation. ChemMedChem. https://doi.org/10.1002/cmdc.202300002
Vancouver
Quancard J, Vulpetti A, Bach A, Cox B, Guéret SM, Hartung IV, et al. The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Hit Generation. ChemMedChem. 2023. doi:10.1002/cmdc.202300002
BibTeX
@article{Quancard2023,
author = {Quancard, Jean and Vulpetti, Anna and Bach, Anders and Cox, Brian and Guéret, Stéphanie M and Hartung, Ingo V and Koolman, Hannes F and Laufer, Stefan and Messinger, Josef and Sbardella, Gianluca and Craft, Russell},
title = {The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Hit Generation},
journal = {ChemMedChem},
year = {2023},
doi = {10.1002/cmdc.202300002}
}
EUVIMED